[18F]FAraG PET Imaging for Analysis of Biodistribution in Cancer Patients Expected to Undergo Immunotherapy and/or Radiation Therapy
Study of the Kinetics, Dosimetry and Safety of [18F]F-AraG (VisAcT), a Positron Emission Tomography Tracer for Imaging the Activation of the Immune System in Cancer Patients Who Have Received or Are Expected to Receive Immunotherapy and/or Radiation Therapy
Sponsor: CellSight Technologies, Inc.
A PHASE1 clinical study on Cancer, this trial is ongoing. The trial is conducted by CellSight Technologies, Inc. and has accumulated 11 data snapshots since 2017. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
11 versions recorded-
Jan 2025 — Present [monthly]
Unknown PHASE1
Status: Recruiting → Unknown
-
Sep 2024 — Jan 2025 [monthly]
Recruiting PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE1
-
Jan 2023 — Jul 2024 [monthly]
Recruiting PHASE1
-
Sep 2021 — Jan 2023 [monthly]
Recruiting PHASE1
▶ Show 6 earlier versions
-
Jan 2021 — Sep 2021 [monthly]
Recruiting PHASE1
-
Aug 2020 — Jan 2021 [monthly]
Recruiting PHASE1
-
Mar 2019 — Aug 2020 [monthly]
Recruiting PHASE1
-
Jun 2018 — Mar 2019 [monthly]
Recruiting PHASE1
-
Aug 2017 — Jun 2018 [monthly]
Recruiting PHASE1
-
Jun 2017 — Aug 2017 [monthly]
Recruiting PHASE1
First recorded
May 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- CellSight Technologies, Inc.
- UCSF Imaging Center at China Basin
For direct contact, visit the study record on ClinicalTrials.gov .